21 CFR Part 211 · Current Good Manufacturing Practice for Finished Pharmaceuticals

21 CFR 211.34

Consultants

21 CFR 211.34 is the regulation titled “Consultants” in 21 CFR Part 211, Current Good Manufacturing Practice for Finished Pharmaceuticals. Since 2021, 8 FDA warning letters have cited it.

Letters citing it
8 since 2021
Jan 1 to Oct 30, 2026
1 against 0 on the same dates in 2025
Most often cited with
21 CFR 211.22, in 5 letters
Closed out
13% of these letters have a published close-out
See the 8 letters citing 21 CFR 211.34 →

Letters citing it, by year issued

All are drug letters. 2026 runs to Oct 30, 2026. Pick a year to see its letters.

  1. 12021
  2. 42022
  3. 12023
  4. 12024
  5. 02025
  6. 12026

The regulation

Read the text of 21 CFR 211.34 (eCFR, as of Sep 1, 2026)

Consultants advising on the manufacture, processing, packing, or holding of drug products shall have sufficient education, training, and experience, or any combination thereof, to advise on the subject for which they are retained. Records shall be maintained stating the name, address, and qualifications of any consultants and the type of service they provide.

Text from eCFR as of Sep 1, 2026.

Cited alongside it

Regulations that appear in the same letters as 21 CFR 211.34.

Latest letters citing it

The 3 letters citing 21 CFR 211.34 that FDA posted most recently.

See the 8 letters citing 21 CFR 211.34 →
For regulated teams

Put this kind of reading to
work on your own records.

Botable builds and runs a custom AI layer around the software you already use, so your team can do the job you hired them for.

Counts include every citation in a letter, as the Letters filter does. How this database is built.

Every letter by dateHow this database is built

FDA Warning Letter Alerts

Share this view

Send the same filters, search and view to a colleague.

You choose what to post or send. Sharing a link does not change access to this site.